Is IBM's selloff an opportunity? Here's one case for the beaten-down stock.

IBM shares have fallen 19% in 2026, sharply lagging the S&P 500's 13% gain, following a preliminary July earnings release that flagged weaker-than-expected results and pressure in its mainframe business. Evercore ISI argues the selloff has created a compelling buying opportunity, suggesting investors are effectively receiving IBM's quantum-computing initiatives for free despite elevated market skepticism.

Analysis

The investable question is not whether IBM's quantum program has strategic value, but whether the core software and infrastructure franchise can stabilize before investors assign a permanently lower multiple. Quantum should be treated as a long-dated call option rather than a near-term earnings driver: commercialization timelines remain uncertain, and pure-play quantum names such as IONQ and RGTI offer more direct but materially higher-beta exposure. The nearer-term valuation debate will hinge on whether recurring Red Hat/software growth and consulting backlog can offset any deterioration in high-margin infrastructure mix.

A weak mainframe cycle has outsized implications because it can pressure both revenue mix and operating leverage, not simply one product line. If customer upgrades are deferred rather than cancelled, IBM's installed-base lock-in could support a recovery over the next 1-3 quarters; if workload migration to public cloud and AI-native architectures is accelerating, the market may be correctly discounting a structurally lower terminal growth rate. Microsoft, AWS and Google are the relevant competitive read-throughs: stronger enterprise migration commentary from those platforms would weaken the IBM recovery case.

Consensus may be over-weighting the near-term earnings reset while under-weighting the company's ability to monetize hybrid-cloud and AI integration through its enterprise sales force. Conversely, the bullish "free quantum option" framing is not enough on its own to support a rerating: absent disclosed bookings, external customer adoption, or a credible route to profitable quantum services, it should receive little incremental NAV credit. The key falsifiers are another reduction in full-year free-cash-flow expectations, sustained software growth deceleration, or evidence that infrastructure weakness extends beyond a normal product-cycle trough.

Key Decisions for Investors

• Build only a staged long IBM position ahead of the next earnings release, beginning at one-third size; add only if management confirms stable recurring-software growth and does not reduce free-cash-flow guidance. Frame a 10-15% rerating over 3-6 months against an 8% downside stop, for roughly 1.5-2.0x reward/risk.
• Use IBM as a lower-beta enterprise-AI/hybrid-cloud value exposure rather than as a quantum-computing trade; investors seeking quantum upside should keep any IONQ or RGTI exposure separately sized as venture-like risk rather than attributing that optionality to IBM's base-case valuation.
• Monitor next-quarter infrastructure bookings, Red Hat subscription metrics, consulting signings and free-cash-flow guidance. A second sequential deterioration in two or more of these indicators should invalidate the long thesis and favor avoiding the name rather than averaging down.
• For portfolio hedging over the next 1-3 months, pair a tactical long IBM position with an underweight in enterprise software names carrying premium AI multiples and weak cash conversion; the intended exposure is a recovery in IBM-specific execution, not broad AI-multiple expansion.